NASDAQ:RLAY Relay Therapeutics (RLAY) Stock Price, News & Analysis $7.14 -0.12 (-1.65%) (As of 08/27/2024 ET) Add Compare Share Share Today's Range$7.00▼$7.3150-Day Range$6.26▼$9.4852-Week Range$5.70▼$12.14Volume425,178 shsAverage Volume1.19 million shsMarket Capitalization$947.78 millionP/E RatioN/ADividend YieldN/APrice Target$21.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Relay Therapeutics alerts: Email Address Relay Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside203.5% Upside$21.67 Price TargetShort InterestBearish6.82% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 2 Articles This WeekInsider TradingSelling Shares$988,396 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.91) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.48 out of 5 starsMedical Sector474th out of 921 stocksBiological Products, Except Diagnostic Industry72nd out of 142 stocks 4.5 Analyst's Opinion Consensus RatingRelay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRelay Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Relay Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.82% of the outstanding shares of Relay Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 2.61%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLAY. Previous Next 2.1 News and Social Media Coverage News SentimentRelay Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Relay Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for RLAY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $988,396.00 in company stock.Percentage Held by InsidersOnly 4.32% of the stock of Relay Therapeutics is held by insiders.Percentage Held by Institutions96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relay Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Relay Therapeutics are expected to decrease in the coming year, from ($2.91) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Relay Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This Could be Worse than Trump’s Assassination Attempt”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About Relay Therapeutics Stock (NASDAQ:RLAY)Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More RLAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLAY Stock News HeadlinesAugust 1, 2024 | insidertrades.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $92,276.80 in StockJuly 30, 2024 | insidertrades.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells $332,923.42 in StockAugust 28, 2024 | Paradigm Press (Ad)Forget the Polls, Here’s What Will Happen this ElectionAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 8, 2024 | finanznachrichten.deRelay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate HighlightsAugust 6, 2024 | msn.comRelay Therapeutics GAAP EPS of -$0.69 beats by $0.04August 6, 2024 | globenewswire.comRelay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate HighlightsJuly 24, 2024 | finance.yahoo.comWe're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn RateJune 24, 2024 | seekingalpha.comRelay Therapeutics: A 'Concept' StockAugust 28, 2024 | Paradigm Press (Ad)Forget the Polls, Here’s What Will Happen this ElectionAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… June 6, 2024 | globenewswire.comRelay Therapeutics Discloses Three New Programs at New Program & Platform EventJune 5, 2024 | globenewswire.comRelay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608May 21, 2024 | globenewswire.comRelay Therapeutics to Participate in Upcoming Investor ConferencesMay 13, 2024 | globenewswire.comRelay Therapeutics to Host New Program and Platform Event on June 6, 2024May 10, 2024 | msn.comRelay Therapeutics upgraded by Barclays ahead of data readoutMay 10, 2024 | msn.comBarclays Upgrades Relay Therapeutics (RLAY)May 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst ConfidenceMay 4, 2024 | finance.yahoo.comRelay Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 2, 2024 | finance.yahoo.comRelay Therapeutics Outperforms Revenue Expectations in Q1 2024See More Headlines Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today8/27/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLAY CUSIPN/A CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$21.67 High Stock Price Target$30.00 Low Stock Price Target$14.00 Potential Upside/Downside+203.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-341,970,000.00 Net MarginsN/A Pretax Margin-916.89% Return on Equity-43.66% Return on Assets-38.38% Debt Debt-to-Equity RatioN/A Current Ratio15.64 Quick Ratio15.64 Sales & Book Value Annual Sales$35.21 million Price / Sales26.92 Cash FlowN/A Price / Cash FlowN/A Book Value$5.90 per share Price / Book1.21Miscellaneous Outstanding Shares132,742,000Free Float127,008,000Market Cap$947.78 million OptionableOptionable Beta1.66 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Independent Chairman Comp: $92.5kDr. Sanjiv K. Patel M.A. (Age 50)M.B.A., M.D., MBBS, CEO, President & Director Comp: $1.08MDr. Mark Murcko Ph.D. (Age 64)Co-Founder & Director Comp: $60kMr. Thomas Catinazzo (Age 47)Chief Financial Officer Comp: $663.99kMr. Brian R. Adams J.D. (Age 50)Chief Legal Officer & Secretary Comp: $627.72kMr. Peter RahmerChief Corporate Development OfficerDr. Donald A. Bergstrom M.D. (Age 52)Ph.D., President of Research & Development Comp: $1.37MDr. Deborah Palestrant M.B.A.Ph.D., Vice President of Corporate Development & StrategyMr. Jim Watters Ph.D.Chief Scientific Officer of Late ResearchDr. Beni B. Wolf M.D.Ph.D., Chief Medical Officer & Head of Precision MedicineMore ExecutivesKey CompetitorsVir BiotechnologyNASDAQ:VIRAllogene TherapeuticsNASDAQ:ALLOFate TherapeuticsNASDAQ:FATEFive Prime TherapeuticsNASDAQ:FPRXBiohavenNYSE:BHVNView All CompetitorsInsiders & InstitutionsDriehaus Capital Management LLCBought 218,302 shares on 8/16/2024Ownership: 0.460%Algert Global LLCBought 174,953 shares on 8/16/2024Ownership: 0.356%The Manufacturers Life Insurance Company Sold 19,598 shares on 8/15/2024Ownership: 0.161%Caxton Associates LPSold 23,248 shares on 8/15/2024Ownership: 0.080%Susquehanna Fundamental Investments LLCBought 38,117 shares on 8/15/2024Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions RLAY Stock Analysis - Frequently Asked Questions How have RLAY shares performed this year? Relay Therapeutics' stock was trading at $11.01 at the start of the year. Since then, RLAY shares have decreased by 35.1% and is now trading at $7.14. View the best growth stocks for 2024 here. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04. When did Relay Therapeutics IPO? Relay Therapeutics (RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO. Who are Relay Therapeutics' major shareholders? Relay Therapeutics' top institutional investors include Dimensional Fund Advisors LP (1.15%), Logos Global Management LP (0.98%), Millennium Management LLC (0.86%) and Renaissance Technologies LLC (0.68%). Insiders that own company stock include Mark Murcko, Sanjiv Patel, Donald A Bergstrom, Peter Rahmer, Thomas Catinazzo, Brian Adams and Andy Porter. View institutional ownership trends. How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG) and DraftKings (DKNG). This page (NASDAQ:RLAY) was last updated on 8/28/2024 by MarketBeat.com Staff From Our PartnersNew Wealth Shift Creates Potential 10x Opportunity in Next 18 MonthsFamous Tech Billionaires Endorse America’s New Money A radical new type of money is about to upend our enti...Banyan Hill Publishing | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.